Forian Inc. expects FY25 revenue of $28-$30mln.
ByAinvest
Wednesday, May 14, 2025 4:54 pm ET1min read
FORA--
Key Financial Highlights:
- Revenue: Forian reported $7.1 million in revenue for the quarter ended March 31, 2025, an increase of 45% compared to $4.9 million in the prior year [1].
- Net Loss: The company incurred a net loss of $1.1 million, or $0.04 per share, compared to a net loss of $1.2 million, or $0.04 per share, in the prior year [1].
- Adjusted EBITDA: Adjusted EBITDA was $(0.1) million for the quarter, compared to $0.1 million in the prior year [1].
Operational Milestones:
- Solid Revenue Growth: Forian began the year with its highest quarterly revenue to date, reflecting acquisition impacts, strategic contract renewals, and new logos [1].
- Integration and Investment: The company accelerated contracting and investments and integrated new clinical data feeds, easing upstream data supply disruptions [1].
- Pharmaceutical Expansion: Forian achieved continued growth from pharmaceutical and biotech companies, reflecting increased adoption of its data solutions [1].
- Strategic M&A: The first full quarter integrating Kyber Data Science's platform, predictive analytics, and financial services markets to Forian's business [1].
Full Year 2025 Outlook:
Forian expects revenue to be in the range of $28 to $30 million and adjusted EBITDA to be in the range of $(1.0) to $1.0 million for the year ending December 31, 2025 [1].
References:
[1] https://www.nasdaq.com/press-release/forian-inc-announces-first-quarter-2025-financial-results-2025-05-14
Forian Inc. expects FY25 revenue of $28-$30 million. The company provides data management capabilities and analytics for life sciences, healthcare payers and providers. Its operations consist of subscription and services-based solutions for commercial, Real World Evidence, and market access. Forian also offers machine learning applications for the financial services community.
NEWTOWN, PA - May 14, 2025 (NEWMEDIAWIRE) - Forian Inc. (Nasdaq: FORA), a leading provider of data science-driven information and analytics solutions, today announced its first-quarter 2025 financial results. The company reported a significant increase in revenue and a decrease in net loss compared to the same period last year. Forian's CEO, Max Wygod, highlighted the company's positive momentum and solid assimilation of the Kyber business.Key Financial Highlights:
- Revenue: Forian reported $7.1 million in revenue for the quarter ended March 31, 2025, an increase of 45% compared to $4.9 million in the prior year [1].
- Net Loss: The company incurred a net loss of $1.1 million, or $0.04 per share, compared to a net loss of $1.2 million, or $0.04 per share, in the prior year [1].
- Adjusted EBITDA: Adjusted EBITDA was $(0.1) million for the quarter, compared to $0.1 million in the prior year [1].
Operational Milestones:
- Solid Revenue Growth: Forian began the year with its highest quarterly revenue to date, reflecting acquisition impacts, strategic contract renewals, and new logos [1].
- Integration and Investment: The company accelerated contracting and investments and integrated new clinical data feeds, easing upstream data supply disruptions [1].
- Pharmaceutical Expansion: Forian achieved continued growth from pharmaceutical and biotech companies, reflecting increased adoption of its data solutions [1].
- Strategic M&A: The first full quarter integrating Kyber Data Science's platform, predictive analytics, and financial services markets to Forian's business [1].
Full Year 2025 Outlook:
Forian expects revenue to be in the range of $28 to $30 million and adjusted EBITDA to be in the range of $(1.0) to $1.0 million for the year ending December 31, 2025 [1].
References:
[1] https://www.nasdaq.com/press-release/forian-inc-announces-first-quarter-2025-financial-results-2025-05-14
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet